Parsippany, N.J., March 8, 2016 – Pacira Pharmaceuticals, Inc. has selected Coyne PR to drive brand awareness, education and activation for EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid local analgesic administered into the surgical site to produce postsurgical pain control, among healthcare professionals, patients and caregivers. The Parsippany-based pharmaceutical company is focused on the development, commercialization and manufacture of new pharmaceutical products for the acute care marketplace, based on its proprietary DepoFoam® drug delivery technology.
Pacira hired Coyne to develop and manage integrated, multi-channel campaigns that drive awareness of EXPAREL among healthcare professionals, while educating patient and caregiver audiences that they have postsurgical pain control options, which could minimize or eliminate the need for opioids. Opioid use in the country is a growing issue as it’s estimated that one in every 15 patients who receive opioids (also called prescription painkillers or narcotics) following surgery ends up using these medications long-term, which can result in tolerance, dependency and addiction.
"Patient education and empowerment represents the foundation of our partnership with Coyne,” said Amber Sears, Senior Director of Corporate Communications for Pacira. “We have an opportunity to address a growing opioid issue in the U.S. through our efforts, and we’re excited to work with Coyne in taking this story to the right audiences nationally."
"EXPAREL represents an excellent non-opioid option for postsurgical pain, which can reduce or eliminate the need for supplemental opioids after surgery,” said Kelly Dencker, Senior Vice President and Director of the Healthcare practice at Coyne PR. “Pacira has undertaken an important educational campaign built around the platform of patient choice when it comes to postsurgical pain control, and we’re thrilled to collaborate with them in bringing it to life.”
ABOUT PACIRA
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
ABOUT COYNE PR
Coyne PR is a full-service, integrated communications agency with expertise in a variety of industries. Prominent clients include The Walt Disney Company, Hard Rock International, Red Robin Gourmet Burgers, Chrysler, Goodyear Tire & Rubber Company, Shell Lubricants, Columbia Business School and Pfizer. Fueled by the agency’s mission to be the best place to work, employees deliver high-profile programs that drive visibility, engagement and growth for many of the world's most-trusted brands. The agency has evolved far beyond its PR roots with a dedicated social media practice, an award-winning digital design group and a full advertising and marketing team. Coyne has won more than 750 industry honors in the past decade, including Midsize Agency of the Year by PRWeek, Consumer Agency of the Year, Best Agency to Work For in America and Small Agency of the Year by The Holmes Report. The agency is also a member of the Worldcom Public Relations Group, the world’s leading partnership of independently owned PR firms.+
